Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Shattuck Labs Inc

STTK ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$7.53

▲ +3.86%

Market Cap $755.74M · Vol 209.71K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$755.74M

Small Cap

Div Yield

N/A

EPS Growth

+34.21%

YoY

RSI (14)

53.70

Momentum

Beta

1.14

vs Market

52W High

$8.31

9.39% below

52W Low

$0.90

736.67% above

Volume

209.71K

Avg 371.42K

P/B

2.80

Price-to-book

ROE

-60.25%

Return on equity

Free Float

85.71%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Shattuck Labs Inc (STTK) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does STTK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.48%

+4.44%

+23.65%

+87.78%

YTD

+106.30%

+741.62%

+228.10%

-62.26%

Financials & Valuation

TTM · Annual

Total Revenue	$1.00M
Net Income	$-48,809,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-5,140.80%
Net Profit Margin	-4,880.90%
ROE	-60.25%
ROA · ROIC	-53.61% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	253.99
P/B	2.80
P/FCF	N/A
EPS Growth	+34.21%
Outstanding Shares	100.36M

Technical Indicators

50-Day SMA	$6.69
200-Day SMA	$5.22
RSI (14)	53.70
Beta	1.14
52-Week High	$8.31
52-Week Low	$0.90

Volume Today	209.71K
Avg Daily Volume (30D)	371.42K
Relative Volume	0.56x
Volatility (10D)	44.85
Volatility (30D)	69.80
Free Float	85.71%

Analyst Consensus

BUY

Current Price $7.53

Mean Target $14.43

52W Low$0.90 52W High$8.31

Current

Target

$0.90 $8.31

Current Analyst target

+91.61% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00V776CR6

ISINUS82024L1035

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.